Abstract: The invention relates to a dosing regimen for sedation with the fast-acting benzodiazepine CNS 7056 in combination with an opioid, in particular fentanyl, whereas CNS 7056 is given in a dose of 2 to 20 mg, preferably between 4 and 9 mg and most preferably between 5 and 8 mg.

Abstract: The present invention relates to the use of non-bioconvertible C3-substituted pregnenolone derivatives of formula (I), with no significant affinity for hormonal receptors or receptors of the central nervous system, in the treatment of substance use disorders, and in particular of alcohol use disorder.

Abstract: Polyethylene glycol (PEG)-conjugated glucocorticoid prodrugs, methods of preparation, and use for the treatment of diseases and disorders are disclosed. In particular, PEG-conjugated dexamethasone compounds and methods of using them for treating inflammatory and autoimmune diseases, including but not limited to lupus, are disclosed.

Abstract: Pharmaceutical compositions, methods for treating various issues of the eyes, and methods of preparing such compositions are described. These pharmaceutical compositions may be for treating glaucoma, in preparation of eye surgery, during eye surgery, various post-op care (e.g., after cataract surgery, laser eye surgery, and the like), for treating dry eyes, and/or for promoting eyelash growth. These pharmaceutical compositions may comprise such active ingredients (APIs) as: timolol, latanoprost, brimonidine tartrate, dorzolamide, moxifloxacin HCl, dexamethasone PO4, phenylephrine HCl, lidocaine HCl, ketorolac tromethamine, bromfenac, prednisolone PO4, gatifloxacin, amniotic cytokine extract (ACE), prostaglandin E2 (PGE2), and combinations thereof.

Abstract: The present invention relates to a composition for preventing or treating muscle diseases or improving muscular function, containing fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract. According to the present invention, fucosterol, Sargassum fulvellum, a Sargassum fulvellum dried powder, a Sargassum fulvellum extract, Sargassum fusiforme, a Sargassum fusiforme dried powder or a Sargassum fusiforme extract increases the protein expression of p-mTOR, which is a main gene involved in muscle protein synthesis, inhibits the mRNA expression of MuRF-1 and atrogin-1 involved in muscle protein degradation, and increases the mRNA expression of MyoD and myogenin involved in muscle differentiation, thereby having an effect of remarkably increasing muscular function.

Abstract: The invention provides inhibitors of ?-crystallin aggregation and methods of using ?-crystallin aggregation inhibitors to, e.g., treat or prevent cataracts in a subject having or at risk of developing cataracts. The invention further provides high throughput methods of screening compounds for modulation of protein thermal stability, the method comprising contacting a protein with each of a plurality of test compounds; and (b) measuring the melting transition (Tm) of the protein in the presence of each of the plurality of test compounds, wherein a compound that decreases or increases the apparent Tm by at least 2 standard deviations is identified as a pharmacological protein chaperone.

Abstract: Disclosed herein are conditioning regimens and methods for inducing MHC- or HLA-mismatched mixed chimerism by conditioning a recipient with radiation-free, low-doses of cyclophosphamide (CY), pentostatin (PT), and anti-thymocyte globulin (ATG) prior to transplantation of donor bone marrow cells. In certain embodiments, the donor bone marrow cells may be CD4+ T-depleted bone marrow cells. The conditioning regimens and methods may also include administering one or more populations of conditioning donor cells selected from donor CD4+ T-depleted spleen cells, donor CD8+ T cells, and donor G-CSF-mobilized peripheral blood mononuclear cells. The conditioning regimen is clinically acceptable and can be used for treating hereditary hematological diseases and autoimmune diseases, as well as for promoting organ transplantation immune tolerance.

Abstract: Various embodiments of a gut microbiome modulating composition comprises a blend of a polyphenol and an oligosaccharide. Various embodiments of the polyphenol may comprise at least approximately 5% by weight chlorogenic acid. Various embodiments of the oligosaccharides may be standardized to a degree of polymerization of at least three to reduce digestibility. Administration of an effective amount of the gut microbiome modulating composition to a person or animal may stimulate the growth of at least one of Akkermansia muciniphila, Lactobacillus, and Bifidobacterium bacteria in the colon, which may reduce permeability of the colon, increases short chain fatty acid production in the colon, and/or modulate causes immunomodulation of human colon cells. The gut microbiome modulating composition may provide protective effects against obesity-related chronic diseases.

Abstract: The invention generally relates to anti-aging compositions and methods for using the anti-aging compositions. In one aspect, the invention provides a method for preventing cellular aging in a cell of a subject, the method comprising the step of providing to the cell an effective amount of at least one lithium compound or a pharmaceutically acceptable salt thereof, and an effective amount of at least one glycyrrhizie triterpenoid compound or a pharmaceutically acceptable salt thereof, thereby preventing the cell from aging. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

Abstract: Methods and systems for identifying and treating patients with cancers that can bind E-selectin are disclosed. E-selectin-binding cancers are identified by their cell surface expression sialyl Le3 and sialyl Le3 carbohydrate epitopes, and such cancers can be identified by antibodies that bind to sialyl Lea/x, such as HECA-452. Such cancers can be treated with antagonists of E-selectin such as glycomimetic compounds and with immunotherapies targeting the cell surface carbohydrates containing the sialyl Lea/x domains to block and/or disrupt the binding of E-selectin.

Abstract: Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

Abstract: Provided, among other things, is a method of treating or ameliorating pulmonary infection in a cystic fibrosis patient comprising pulmonary administration of an effective amount of a liposomal/complexed antiinfective to the patient, wherein the (i) administrated amount is 50% or less of the comparative free drug amount, or (ii) the dosing is once a day or less, or (iii) both.

Abstract: Pharmaceutical compositions showing the ability to inhibit or suppress replication of a filovirus in an individual are disclosed. The disclosed compositions are useful for treating, reventing, or reducing the spread of infections by filovirus. A method includes administering at least one agent of the present disclosure to an individual infected with or exposed to a filovirus, wherein the step of administering is carried out for a suitable time period so that the individual is treated; and determining whether the individual has been treated, wherein the step of determining includes one of measuring an inhibition in viral replication, measuring a decrease in viral load, or reducing at least one symptom associated with the filovirus.

Abstract: Pharmaceutical compositions comprising a first anti-acne compound, a second anti-acne compound, and an anti-photoaging compound are described. Methods for the treatment of acne and photoaging using the compositions are also described.

Abstract: Disclosed herein are compounds and methods for modulating C9orf72 transcript. Such compounds and methods are useful to treat, prevent, or ameliorate neurodegenerative diseases in an individual in need thereof.

Abstract: The invention is directed to a method for treating the 22q11 deletion syndrome (22q11 DS) and schizophrenia (SCZ) by replenishment of decreased levels of miR-338-3p in thalamic neurons.

Abstract: A compound and method for treating a patient with multiple sclerosis symptoms is disclosed. The compound includes from approximately 1 milligrams to approximately 4 milligrams of vitamin B12, from approximately 150 milligrams to approximately 300 milligrams of biotin, from approximately 1 milligram to approximately 4 milligrams of folate, from approximately 2000 international units to approximately 10,000 international units of vitamin D3, from approximately 100 milligrams to approximately 1000 milligrams of vitamin C, from approximately 300 milligrams to approximately 1200 milligrams of n-acetylcysteine, from approximately 10 milligrams to approximately 50 milligrams of green coffee bean extract, and from approximately 100 milligrams to approximately 1000 milligrams of turmeric concentrate.

Abstract: Disclosed are compositions comprising synergic combinations of xyloglucans and plant or animal proteins, which are useful in the treatment of intestinal disorders.

Abstract: A task of the invention is to provide an art that inhibits the hemorrhagic activity exhibited by sulfated glycosaminoglycans, as well as a material, a medical material, and a drug that use a sulfated glycosaminoglycan while being free of the hemorrhaging problems caused by sulfated glycosaminoglycans and that can exhibit an excellent therapeutic effect on biological tissues. The present invention relates to an inhibitor of the hemorrhagic activity originating from sulfated glycosaminoglycans, the inhibitor having a cationized chitosan as an active ingredient.

Abstract: The present invention concerns a novel, sterile and injectable aqueous composition, that is heat-sterilised, comprising at least crosslinked hyaluronic acid, or one of the salts of same, and one or more fatty acids, characterised in that the mass proportion of water is greater than 51% of the total mass, the mass proportion of fatty acid is less than 45% of the total mass, the viscoelasticity properties are such that the ratio G?/G? at 0.7 Hz is less than 0.70; a method for preparing said composition; and the use of said composition for aesthetic and therapeutic applications.

Abstract: This invention is directed to, inter alia, compositions comprised of pentosan polysulfate sodium (PPS) components and methods for making such compositions and using the same for the treatment of sickle cell disease (SCD). The disclosed compositions possess superior bioavailability as well as P-selectin blocking activity for the treatment of sickle-cell disease (SCD). Methods for using the same are additionally provided herein. Also provided herein is a method for detecting or quantifying PPS or a PPS fraction in solutions or in a biological sample obtained from an animal or an individual.

Abstract: Methods of treating cancer in a subject by administering a therapeutically effective amount of a polycationic polymer to the subject are provided. Methods of treating cancer in a subject by contacting a bodily fluid from a subject with a polycationic polymer are also provided. Methods of detecting cancer or metastasis of cancer by obtaining a sample from a subject and determining the level of circulating free DNA (cfDNA), cfRNA, inorganic polyphosphates or the number of exosomes or nucleosomes in the sample are also provided.

Abstract: Provided herein are methods and compositions for the treatment and/or prevention of: suicide, homicide, and/or self-harming behavior, comprising administration of a composition comprising xenon.

Abstract: The present invention relates to a composition comprising chlorine dioxide useful in the treatment of active infections of the eye, as well as prophylaxis and treatment of such infections. The invention also relates to uses of compositions including effective amounts of chlorine dioxide in the eye to obtain benefit without detrimentally affecting the eye.

Abstract: The present invention relates to the use of a zeolite as a chemical agent with additional cytotoxic effects used in pleurodesis in the cases of liquid accumulation (pleural effusion) or air accumulation (pneumothorax) in the pleural cavity of lungs.

Abstract: The present disclosure provides for systems and methods including pre-moistened dressings with a treatment composition, wherein the dressings can include a water proof occlusive material on one side and an absorbing material for the treatment composition, thereby enabling direct contact transfer of the treatment composition to the skin surface. The treatment composition can include 2-70% wt/vol of a magnesium complex in water. The dressings can be replaced every one to three days for a total treatment time of one to 36 days or more. The treatment systems can be used to treat psoriasis and chronic inflammation, among others.

Abstract: Provided herein is a topical composition and related methods for making and using the composition. In a first aspect, the topical composition comprises a magnesium salt (e.g. magnesium chloride) dissolved in an anhydrous or non-aqueous solvent. Exemplary solvents comprise a monohydric aliphatic alcohol, and a polyol.

Abstract: Provided is a therapeutic agent for skin wounds or rough skin that includes at least one selected from the group consisting of zinc sulfate, zinc chloride, zinc carbonate, zinc hydroxide, and zinc oxide, may include a pharmaceutically acceptable carrier, and is effective in regenerating tissue.

Abstract: A method for repairing an injury of cartilage in a patient by local administration of a zinc or manganese agent or use of an implantable device for delivery of an a zinc or manganese agent. Implantable devices containing a zinc or manganese agent and methods of making these implantable devices are also disclosed.

Abstract: Methods of inhibiting the virulence of a pathogen to treat a gastrointestinal spasm in a subject, without killing the pathogen, are provided. The methods can include administering an effective amount of a formulation to treat the gastrointestinal spasm, the formulation having a tannin combined with a hydroxyl radical in a pharmaceutically acceptable excipient as a binding pair, the tannin releasing in an oxidized state from the hydrogen donor after oral administration of the formulation in the subject; wherein, the composition at least inhibits a gastrointestinal spasm in the subject when compared to a second subject in a control group in which the composition was not administered.

Abstract: Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.

Abstract: Aspects of the disclosure relate to methods of treating a subject who has had a Glioblastoma Multiforme (GBM) tumor surgically removed.

Abstract: Provided herein are pathogen-inactivated plasma compositions and methods for treating a disease or condition using pathogen-inactivated plasma compositions.

Abstract: Provided are cells, e.g., engineered immune cells, expressing recombinant or engineered molecules involved in metabolic pathways, such as those that promote or inhibit one or more metabolic steps, reactions, or pathways, for example, in T cells. Such molecules include those that induce or repress a particular functional outcome or metabolic event, for example, one that promotes differentiation or reprogramming into a particular phenotypic state, such as memory, long-lived, activated or activatable, non-exhausted, phenotype or stem-like phenotype. The cells generally further express an immune receptor, such as an antigen receptor, which may be an engineered receptor, such as a CAR or recombinant TCR, or may be a natural immune receptor. Also provided are cells, such as T cells, expressing such molecules and combinations thereof, compositions comprising such cells, nucleic acids such as vectors encoding the same, and methods of administration to subjects in adoptive cell therapy.

Abstract: This disclosure relates to the genetic modification of DNMT3A gene in immune cells. In certain embodiments, the modified immune cells may be used in adoptive T cells therapies to enhance immune responses against cancer or chronic infections. In certain embodiments, the disclosure relates to deleting, changing, or inserting nucleotides within the DNMT3A gene in immune cells, e.g., human CD8 T cells, such that the DNMT3A gene product does not function for methylation. In certain embodiments, modification of the DNMT3A gene provides an improvement in antigen-specific T cells functions and/or an enhancement of the longevity of the cells.

Abstract: Provided herein is technology relating to immunotherapy and particularly, but not exclusively, to compositions, methods, and kits for immunotherapy and activation of T cells.

Abstract: The present invention provides a method for producing platelets, including the step of culturing megakaryocyte cells in a culture solution in a culture vessel, wherein in the culturing step, the culture solution is stirred by a stirring blade moving reciprocally.

Abstract: Methods for production of platelets from pluripotent stem cells, such as human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) are provided. These methods may be performed without forming embryoid bodies or clusters of pluripotent stem cells, and may be performed without the use of stromal inducer cells. Additionally, the yield and/or purity can be greater than has been reported for prior methods of producing platelets from pluripotent stem cells. Also provided are compositions and pharmaceutical preparations comprising platelets, preferably produced from pluripotent stem cells.

Abstract: The invention relates to exosomes derived from mesenchymal stem cells and well as isolated populations of said exosomes and method for preparing said isolated exosome populations. The invention also relates to a pharmaceutical composition comprising said exosome or isolated exosome population and their use in a method of treating an immune-mediated inflammatory disease in a subject.

Abstract: The present invention discloses methods, compositions and devices for improving tissue regeneration by suppressing the effects of several proinflammatory cytokines such as TNF-? and IFN-?. Compositions and devices of this invention will generally include one or more anti-inflammatory agent(s) capable of reducing the level of TNF-?, IFN-?, or both. Methods for improving tissue regeneration in accordance with this invention will generally have the step of applying a composition or device of the invention to a site in need of the composition or device. Also disclosed are methods for forming composition and devices of the invention and pharmaceutical compositions comprising one or more anti-inflammatory agent(s) effective of inhibiting or reducing the levels of TNF-?, IFN-?, or both.

Abstract: The present disclosure provides inventive cosmetic/dermatological formulations and/or preparations that include mesenchymal stem cells (MSCs), and also provides associated methods for repairing, rejuvenating and/or augmenting skin tissue. The formulations and/or preparations include MSCs that are formulated into creams, lotions, and the like. In one aspect, the MSCs are obtained autogenously. In another aspect, the MSCs are obtained from allogeneic sources. In another aspect, the MSCs may be minimally manipulated. In another aspect, the MSCs may be derived from bone marrow or adipose tissue. In another aspect, the MSCs can be utilized from bone marrow concentrate (BMC) or from adipose stromal vascular fraction (SVF). In another aspect, the MSCs can also be utilized after cell expansion. The associated methods comprise topical application of the cosmetic/dermatological formulations and/or preparations onto skin tissue, resulting in repairing, rejuvenating, and/or augmenting the skin tissue.

Abstract: The present invention relates to a pharmaceutical composition for treating diabetes, which includes a pancreatic islet cell and an elastin-like artificial extracellular matrix (REP), and more particularly, to a pharmaceutical composition for treating diabetes, in which pancreatic islet cells are reacted with an elastin-like artificial extracellular matrix and then the resulting cells are administered along with the elastin-like artificial extracellular matrix, thus increasing a survival rate of the transplanted pancreatic islet cells, rapidly restoring a blood glucose level to normal, and maintaining the restored blood glucose level for a long period of time, and, accordingly, diabetes may be more effectively treated.

Abstract: The present invention relates to the use of insulin-producing cells encapsulated in silanized hydroxypropyl methylcellulose (Si—HPMC) for the treatment of type 1 diabetes. Methods and kits are also provided for restoring and/or maintaining euglycemia in type 1 diabetic patients and in type 1 prediabetic patients.

Abstract: Methods are disclosed for the collection and processing of amniotic material in animals. These methods involve collection of amniotic material directly during parturition or caesarian section in animals for the processing of regenerative wound treatments and tissue repairs without culturing or utilization of any excess manipulation of tissue.

Abstract: Provided herein is technology relating to immunoisolation of cells and tissues, including, but not exclusively, to compositions, methods, and kits for encapsulating cells and/or tissues within an immunoisolating device to protect the cells/or tissues from host immune rejection.

Abstract: Honey-cannabinoid therapeutic compositions and methods.

Abstract: Disclosed is a stable probiotic composition containing Bacillus coagulans MTCC 5856 exhibiting increased viability over wide range of pH and the use of flow cytometry method to enumerate the viable count of Bacillus coagulans MTCC 5856 under various environmental conditions.

Abstract: The present invention relates to a bacterial composition which can be effectively used in the field of sport nutrition, since it is capable of attenuating the decline in sport performance in a subject after a muscle-damaging exercise.

Abstract: The present invention relates to compositions comprising Lactobacillus plantarum 2830 (ECGC 13110402), or mutant strain or strains thereof, for use in the treatment or prevention of hypercholesterolaemia, and in particular reducing the total cholesterol (TC) and low density lipoprotein cholesterol (LDL-C) levels, in an individual. Specific dosage regimes and methods of production are also claimed and described.

Abstract: The present invention provides methods for treating an individual having solid or lymphatic tumor comprising local administration to the site of the tumor an infectious agent an immunomodulator (including a combination of immunomodulators). The methods may further comprise local administration to the site of the tumor inactivated tumor cells. Also provided are compositions and kits for the cancer therapy methods.